Shire upgrades Baxalta cost savings after Q2 earnings beat
 

Shire upgrades Baxalta cost savings after Q2 earnings beat
LONDON, Aug 2 (Reuters) - Drugmaker Shire upgraded its guidance for 2016 on Tuesday, after it hiked the predicted cost saving target for its $32 billion acquisition of rare disease ***** specialist... http://feeds.feedburner.com/~ff/reut...?d=yIl2AUoC8zA http://feeds.feedburner.com/~ff/reut...So:F7zBnMyn0Lo http://feeds.feedburner.com/~ff/reut...So:V_sGLiPBpWU
http://feeds.feedburner.com/~r/reute...~4/FPPVNqIy0hY